AI assistant
BIOGEN INC. — Director's Dealing 2013
Sep 18, 2013
30291_dirs_2013-09-18_1d7c56d9-1884-4726-8139-7f81e99a2c53.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: BIOGEN IDEC INC. (BIIB)
CIK: 0000875045
Period of Report: 2013-09-16
Reporting Person: Sandrock Alfred (Grp SVP, Chief Medical Officer)
Non-Derivative Transactions
| Date | Security | Code | Shares | Price | A/D | Holdings After | Ownership |
|---|---|---|---|---|---|---|---|
| 2013-09-16 | Common Stock | M | 9820 | $49.65 | Acquired | 24320 | Direct |
| 2013-09-16 | Common Stock | S | 9820 | $240.104 | Disposed | 14500 | Direct |
Derivative Transactions
| Date | Security | Exercise Price | Code | Shares | A/D | Expiration | Underlying | Ownership |
|---|---|---|---|---|---|---|---|---|
| 2013-09-16 | Stock Option (Right to Buy) | $49.65 | M | 9820 | Disposed | 2019-02-23 | Common Stock (9820) | Direct |
Footnotes
F1: Exercise/sale pursuant to a trading plan intended to comply with Rule 10b5-1 of the Securities Exchange Act of 1934.
F2: This represents the weighted average price for shares sold at a range between $240.00 (low) and $240.22 (high).
F3: Full information regarding the number of shares sold at each separate price will be provided upon request by the SEC staff, the issuer, or a security holder of the issuer.
F4: The stock options became exercisable in four (4) equal annual installments commencing one year after the grant date of 02/24/09.